Allos Limits RSR13 Brain Metastases NDA To Breast Cancer; User Fee In June
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Allos expects its radiation sensitizer RSR13 (efaproxiral) to receive a priority review for the treatment of brain metastases from breast cancer, placing the user fee goal date in June.